Adalimumab Treatment in Biologically Naïve Crohn's Disease: Relationship with Ectopic MUC5AC Expression and Endoscopic Improvement

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2014 May 16

PMID 24829572

Citations 2

Authors

Tsutomu Mizoshita

Satoshi Tanida

Hironobu Tsukamoto

Keiji Ozeki

Takahito Katano

Hirotaka Nishiwaki

Masahide Ebi

Yoshinori Mori

Eiji Kubota

Hiromi Kataoka

Takeshi Kamiya

Takashi Joh

Affiliations

Soon will be listed here.

Abstract

Background. Adalimumab (ADA) is effective for patients with Crohn's disease (CD). However, there have been few reports on ADA therapy with respect to its relationship with pathologic findings and drug efficacy in biologically naïve CD cases. Methods. Fifteen patients with active biologically naïve CD were treated with ADA. We examined them clinically and pathologically with ectopic MUC5AC expression in the lesions before and after 12 and 52 weeks of ADA therapy, retrospectively. Results. Both mean CD activity index scores and serum C-reactive protein values were significantly lower after ADA therapy (P < 0.001). In the MUC5AC negative group, all cases exhibited clinical remission (CR) and endoscopic improvement at 52 weeks. In MUC5AC positive groups, loss of MUC5AC expression was detected in cases having CR and endoscopic improvement at 52 weeks, while remnant ectopic MUC5AC expression was observed in those exhibiting no endoscopic improvement and flare up after 52 weeks. Conclusions. ADA leads to CR and endoscopic improvement in biologically naïve CD cases. In addition, ectopic MUC5AC expression may be a predictive marker of flare up and endoscopic improvement in the intestines of CD patients.

Citing Articles

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn's Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment.

Suzuki T, Mizoshita T, Sugiyama T, Hirata Y, Kimura Y, Suzuki Y Case Rep Gastroenterol. 2019; 13(1):37-49.

PMID: 31182942 PMC: 6547276. DOI: 10.1159/000496453.

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab.

Mizoshita T, Tanida S, Ozeki K, Katano T, Shimura T, Mori Y Case Rep Gastroenterol. 2016; 10(2):283-91.

PMID: 27462198 PMC: 4939671. DOI: 10.1159/000445105.

References

Tsukamoto T, Inada K, Tanaka H, Mizoshita T, Mihara M, Ushijima T . Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol. 2003; 130(3):135-45. DOI: 10.1007/s00432-003-0519-6. View

Borralho P, Vieira A, Freitas J, Chaves P, Soares J . Aberrant gastric apomucin expression in ulcerative colitis and associated neoplasia. J Crohns Colitis. 2010; 1(1):35-40. DOI: 10.1016/j.crohns.2007.06.006. View

Best W, Becktel J, SINGLETON J, KERN Jr F . Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70(3):439-44. View

Mizoshita T, Tsukamoto T, Inada K, Hirano N, Tajika M, Nakamura T . Loss of MUC2 expression correlates with progression along the adenoma-carcinoma sequence pathway as well as de novo carcinogenesis in the colon. Histol Histopathol. 2006; 22(3):251-60. DOI: 10.14670/HH-22.251. View

Ryu J, Lee H, Park S, Sikder M, Kim J, Hong J . Effect of Prunetin on TNF-α-Induced MUC5AC Mucin Gene Expression, Production, Degradation of IκB and Translocation of NF-κB p65 in Human Airway Epithelial Cells. Tuberc Respir Dis (Seoul). 2013; 75(5):205-9. PMC: 3861376. DOI: 10.4046/trd.2013.75.5.205. View

Shao M, Ueki I, Nadel J . Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11618-23. PMC: 208807. DOI: 10.1073/pnas.1534804100. View

Song K, Lee W, Chung K, Koo J, Yang E, Choi J . Interleukin-1 beta and tumor necrosis factor-alpha induce MUC5AC overexpression through a mechanism involving ERK/p38 mitogen-activated protein kinases-MSK1-CREB activation in human airway epithelial cells. J Biol Chem. 2003; 278(26):23243-50. DOI: 10.1074/jbc.M300096200. View

Schreiber S, Reinisch W, Colombel J, Sandborn W, Hommes D, Robinson A . Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2012; 7(3):213-21. DOI: 10.1016/j.crohns.2012.05.015. View

Mizoshita T, Tanida S, Kusumoto S, Ozeki K, Tsukamoto H, Ebi M . Adalimumab therapy following granulocyte and monocyte adsorptive apheresis in a patient with Crohn's disease accompanied by chronic myeloid leukemia. Clin J Gastroenterol. 2015; 5(4):302-6. DOI: 10.1007/s12328-012-0314-5. View

10.

Sandborn W, Hanauer S, Rutgeerts P, Fedorak R, Lukas M, MacIntosh D . Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56(9):1232-9. PMC: 2701613. DOI: 10.1136/gut.2006.106781. View

11.

Forgue-Lafitte M, Fabiani B, Levy P, Maurin N, Flejou J, Bara J . Abnormal expression of M1/MUC5AC mucin in distal colon of patients with diverticulitis, ulcerative colitis and cancer. Int J Cancer. 2007; 121(7):1543-9. DOI: 10.1002/ijc.22865. View

12.

Shaoul R, Okada Y, Cutz E, Marcon M . Colonic expression of MUC2, MUC5AC, and TFF1 in inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr. 2004; 38(5):488-93. DOI: 10.1097/00005176-200405000-00006. View

13.

DHaens G, Fedorak R, Lemann M, Feagan B, Kamm M, Cosnes J . Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm Bowel Dis. 2009; 15(10):1599-604. DOI: 10.1002/ibd.21034. View

14.

Tatsumi N, Kushima R, Vieth M, Mukaisho K, Kakinoki R, Okabe H . Cytokeratin 7/20 and mucin core protein expression in ulcerative colitis-associated colorectal neoplasms. Virchows Arch. 2006; 448(6):756-62. DOI: 10.1007/s00428-006-0188-3. View

15.

Colombel J, Sandborn W, Rutgeerts P, Enns R, Hanauer S, Panaccione R . Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132(1):52-65. DOI: 10.1053/j.gastro.2006.11.041. View

16.

Mizoshita T, Tanida S, Tsukamoto H, Ozeki K, Katano T, Ebi M . Colon Mucosa Exhibits Loss of Ectopic MUC5AC Expression in Patients with Ulcerative Colitis Treated with Oral Tacrolimus. ISRN Gastroenterol. 2013; 2013:304894. PMC: 3649514. DOI: 10.1155/2013/304894. View

17.

DHaens G, Panaccione R, Higgins P, Vermeire S, Gassull M, Chowers Y . The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol. 2010; 106(2):199-212. DOI: 10.1038/ajg.2010.392. View

18.

Takeda A, Bari S, Iseki H, Otani Y, Koyama I . Gastric differentiation markers expression is potentially useful for the detection of ulcerative colitis-associated dysplasias. Hepatogastroenterology. 2009; 56(89):252-3. View

19.

Rutgeerts P, Vermeire S, Van Assche G . Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?. Gut. 2007; 56(4):453-5. PMC: 1856849. DOI: 10.1136/gut.2005.088732. View

20.

Mori Y, Kataoka H, Miura Y, Kawaguchi M, Kubota E, Ogasawara N . Subcellular localization of ATBF1 regulates MUC5AC transcription in gastric cancer. Int J Cancer. 2007; 121(2):241-7. DOI: 10.1002/ijc.22654. View